HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

nebivolol

selective b1-blocker with additional vasodilator effects which are mediated by the endothelial L-arginine/nitric oxide system

Also Known As:

Berlin-Chemie brand of nebivolol hydrochloride; Lobivon; Menarini brand of nebivolol hydrochloride; Nebilet; R 67555; R-67555; Silostar; Uriach brand of nebivolol hydrochloride; alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; nebivolol hydrochloride

Networked: 444 relevant articles (101 outcomes, 161 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Böhm, Michael: 10 articles (01/2015 - 11/2002)
2.	Sowers, James R: 10 articles (09/2012 - 01/2009)
3.	van Veldhuisen, Dirk J: 9 articles (10/2012 - 01/2007)
4.	Giles, Thomas D: 8 articles (04/2015 - 07/2009)
5.	Tavazzi, Luigi: 8 articles (01/2015 - 11/2002)
6.	Coats, Andrew J S: 8 articles (08/2014 - 11/2002)
7.	Flather, Marcus D: 8 articles (08/2014 - 11/2002)
8.	Fici, Francesco: 8 articles (10/2013 - 08/2005)
9.	Habibi, Javad: 8 articles (09/2012 - 01/2009)
10.	SENIORS Investigators: 7 articles (08/2014 - 02/2005)

Related Diseases

1.	Hypertension (High Blood Pressure) 04/01/2008 - "Nebivolol (Bystolic), a novel, highly cardioselective, third-generation beta-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. " 09/01/2010 - "Nebivolol is effective in mild-to-moderate hypertension and associated with favorable metabolic effects. " 01/01/2007 - "Unlike first generation beta-blockerrs, vasodilator beta-blockerrs such as nebivolol have favorable hemodynamic effects, which may translate into improved cardiovascular outcomes in patients with hypertension." 11/01/2001 - "Therefore, nebivolol may be recommended as an alternative first-line treatment option for the management of patients with mild to moderate essential hypertension." 09/01/2010 - "Nebivolol is effective in treating patients with diabetes suffering from high blood pressure and metabolic syndrome. "
2.	Heart Failure 03/01/2006 - "SENIORS study using nebivolol provides best evidence of effective treatment for heart failure in the elderly." 08/01/2006 - "For example, the vasodilating beta-blocker nebivolol was shown to improve forearm blood flow and arterial stiffness and, in a large clinical study, to significantly reduce morbidity and mortality, independent of left ventricular ejection fraction, among patients with chronic heart failure. " 07/01/2006 - "One long-term trial showed a significant reduction in death and hospital admissions for cardiovascular causes when nebivolol was compared with placebo in patients with heart failure (31.1% vs 65.3%; HR 0.86; 95% CI 0.74 to 0.99). " 01/01/2006 - "Only the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (which used the vasodilating third-generation beta-adrenoceptor antagonist nebivolol) has prospectively investigated the treatment of CHF in elderly patients, including those with preserved systolic function, and demonstrated a significant reduction in the risk of death or cardiovascular hospitalisation. " 01/01/2002 - "Treatment with nebivolol was associated with lowering of systolic and diastolic blood pressure (by 22% and 26%, respectively), significant reduction of left ventricular mass index, improvement of parameters of systolic and diastolic left ventricular function and lowering of NYHA class of heart failure. "
3.	Atherosclerosis 11/01/2009 - "Our study contributes to understand the efficacy of nebivolol on serum protein/peptide profiles during atherosclerosis development." 06/01/2010 - "Our results show that nebivolol treatment may be beneficial to improve oxidative stress parameters in patients with SCF, which are considered to be an early stage of atherosclerosis." 12/01/2009 - "This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice." 12/01/2009 - "Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23+/-1.8% vs. 14.6+/-2.1%) and "cross-section" method (63125+/-8455 microm(2) vs. 91416+/-8357 m(2)). " 11/01/2009 - "Proteomic profiling during atherosclerosis progression: Effect of nebivolol treatment."
4.	Inflammation 01/01/2014 - "The lack of an inhibitory effect of inflammation on the clearance of nebivolol is suggestive of mechanisms other than an efficient hepatic metabolism for its low bioavailability. " 09/01/2009 - "Our aim was to investigate the efficacy of nebivolol in patients with slow coronary flow by monitoring its effects on endothelial function and different markers of inflammation. " 01/01/2014 - "The consistency of response to nebivolol despite inflammation may be due to the predominance of contribution of β2 and β3-AR. " 01/01/2014 - "The action and disposition of nebivolol were, however, unaffected by inflammation despite the reduced β1-AR levels. " 01/01/2014 - "We studied whether response to nebivolol is also reduced by inflammation. "
5.	Reperfusion Injury 10/01/2015 - "The results of this study suggest that nebivolol has protective effects on liver but not on distant organs in a hepatic ischemia/reperfusion injury model. " 10/01/2015 - "These experimental findings indicate that nebivolol may be useful in the treatment of hepatic ischemia/reperfusion injury." 10/01/2015 - "Nebivolol Ameliorates Hepatic Ischemia/Reperfusion Injury on Liver But Not on Distant Organs." 01/01/2008 - "Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats." 11/01/2004 - "The protective effect of nebivolol on ischemia/reperfusion injury in rabbit spinal cord."

Related Drugs and Biologics

1.	carvedilol (Coreg)
2.	Bisoprolol (Concor)
3.	Metoprolol (Lopressor)
4.	Nitric Oxide (Nitrogen Monoxide)
5.	Nitric Oxide Synthase (NO Synthase)
6.	NADPH Oxidase (NAD(P)H oxidase)
7.	Atenolol (Tenormin)
8.	nebivolol
9.	Hydrochlorothiazide (Esidrix)
10.	Amlodipine (Norvasc)

Related Therapies and Procedures

1.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
2.	Ligation
3.	Oral Administration
4.	Aftercare (After-Treatment)
5.	Off-Label Use